Last updated: August 25, 2026
Amoxicillin and clavulanate potassium is a mature, largely generic antibiotic market with high prescription volume, limited patent protection, and low average selling prices. The original Augmentin franchise no longer has meaningful U.S. composition-of-matter or exclusivity protection. Revenue is driven by primary-care prescribing, pediatric infections, dental use, respiratory disease, supply availability, and country-level reimbursement rather than innovation premiums.
The product remains commercially durable because clavulanate protects amoxicillin against beta-lactamase-producing bacteria. Its main risks are generic price erosion, antimicrobial-stewardship restrictions, raw-material disruptions, and competition from other oral antibiotics.
What is the market position of amoxicillin and clavulanate potassium?
Amoxicillin/clavulanate is one of the most widely used oral beta-lactam combinations. In the U.S., the product is marketed under the Augmentin brand and through multiple generic abbreviated new drug applications, or ANDAs. The product is available as tablets, chewable tablets, extended-release tablets, and oral suspension.
The combination is used for selected bacterial infections involving:
- Acute bacterial sinusitis
- Acute otitis media
- Lower respiratory tract infections
- Skin and skin-structure infections
- Urinary tract infections
- Dental and bite-related infections
- Infections caused by beta-lactamase-producing organisms
The product is not a biologic and has no biosimilar pathway. Competition occurs through the ANDA process, therapeutic substitution, wholesaler purchasing, hospital tenders, and retail pharmacy contracting.
| Market characteristic |
Assessment |
| Product type |
Small-molecule fixed-dose combination |
| Originator brand |
Augmentin |
| Active ingredients |
Amoxicillin and clavulanate potassium |
| U.S. regulatory pathway |
NDA for originator; ANDA for generics |
| Patent position |
Mature and largely expired |
| Biosimilar exposure |
None |
| Generic exposure |
High |
| Pricing power |
Low |
| Main demand channel |
Retail pharmacy and outpatient care |
| Key commercial variables |
Volume, shortages, tenders, reimbursement, manufacturing cost |
FDA initially approved Augmentin in 1984. The drug’s commercial life has extended far beyond its core patent term through multiple strengths, pediatric products, extended-release formulations, international registrations, and continued clinical demand. (U.S. Food and Drug Administration [FDA], 2023a)
What patents protect amoxicillin and clavulanate potassium?
The original patent estate protected the combination of amoxicillin or related penicillin antibiotics with clavulanic acid or its salts. The principal U.S. patent associated with the Augmentin combination was U.S. Patent No. 4,525,352, which issued in 1985. Under the patent-term rules applicable to that patent, the 17-year term from issuance ended in 2002, subject to any applicable adjustments or extensions. The core protection is therefore expired.
Later patents and regulatory exclusivities covered specific presentations, ratios, dosage forms, and extended-release products. Those rights did not restore broad exclusivity over standard immediate-release amoxicillin/clavulanate tablets and suspensions.
What formulations are protected by amoxicillin/clavulanate patents?
The commercially relevant formulations include:
| Formulation |
Typical strengths or ratios |
Commercial status |
| Immediate-release tablets |
250/125 mg, 500/125 mg, 875/125 mg |
Generic and brand competition |
| Chewable tablets |
Pediatric strengths |
Generic and brand competition |
| Oral suspension |
125/31.25, 200/28.5, 250/62.5, 400/57 mg per 5 mL |
Generic and brand competition |
| High-dose pediatric suspension |
600/42.9 mg per 5 mL |
Formulation-specific competition |
| Extended-release tablets |
1,000/62.5 mg |
More limited competition than standard tablets |
Formulation complexity remains relevant even after patent expiry. Clavulanate is sensitive to moisture and degradation. Manufacturers must control particle size, blend uniformity, stability, reconstitution performance, and packaging. These requirements create manufacturing and quality barriers, but they do not create a durable patent moat for the standard product.
When does amoxicillin/clavulanate lose exclusivity?
Broad U.S. exclusivity was lost years ago. Generic competition has been established for the standard oral formulations for more than two decades.
| Event |
Approximate timing |
| Original Augmentin U.S. approval |
1984 |
| Core combination patent issued |
1985 |
| Core patent term ended |
2002 |
| Generic competition expanded |
Early 2000s |
| Pediatric and extended-release products introduced |
2000s |
| Current market position |
Mature generic category |
The relevant commercial question is no longer when broad exclusivity ends. It is whether a specific formulation, dosage strength, or manufacturing process retains an enforceable patent or regulatory barrier. For standard tablets and suspensions, the answer is generally no.
What is the Orange Book status of amoxicillin and clavulanate potassium?
The FDA Orange Book identifies approved drug products, therapeutic equivalence ratings, patents, and regulatory exclusivities. Amoxicillin/clavulanate products are regulated as small-molecule prescription drugs. Generic products may receive an AB rating when they meet the FDA’s requirements for pharmaceutical equivalence and bioequivalence to the applicable reference product.
The Orange Book status is fragmented because it includes the originator NDA, discontinued or active presentations, and multiple generic ANDAs. A listing for a particular Augmentin dosage form does not imply that the broader active-ingredient combination remains patent protected.
Key implications are:
- Standard generic tablets can generally be substituted where state pharmacy law permits.
- Suspension products require attention to concentration and reconstitution instructions.
- Extended-release products may have a narrower competitive set.
- A listed patent can apply to a particular product or use rather than to every amoxicillin/clavulanate product.
- Discontinued status for a brand presentation does not eliminate the active generic market.
FDA’s Orange Book should be reviewed by dosage form and strength rather than by active ingredient alone. (FDA, 2023b)
Which companies manufacture amoxicillin and clavulanate potassium?
The competitive field includes the originator brand owner or licensees and a broad group of generic manufacturers. U.S. suppliers have included companies such as Dr. Reddy’s Laboratories, Hikma Pharmaceuticals, Lupin, Sandoz, Teva, Amneal, Aurobindo, and Viatris, subject to changes in product authorization, supply contracts, and market participation.
The market is highly regional. A company may have a strong position in the U.S. retail channel but limited presence in Europe, India, Latin America, or public-sector procurement markets.
How does the product compare with amoxicillin alone?
| Factor |
Amoxicillin alone |
Amoxicillin/clavulanate |
| Spectrum |
Narrower |
Broader against beta-lactamase-producing organisms |
| Cost |
Usually lower |
Usually higher |
| Stewardship profile |
Preferred when adequate |
Reserved for situations requiring broader coverage |
| Adverse-effect burden |
Lower gastrointestinal burden |
Higher diarrhea and gastrointestinal adverse effects |
| Generic competition |
Very high |
Very high |
| Clinical demand |
Broad and durable |
Durable but more guideline-sensitive |
Amoxicillin alone generally has the stronger low-cost position. Amoxicillin/clavulanate retains demand when beta-lactamase coverage is clinically justified. CDC outpatient guidance supports narrower therapy when appropriate and discourages unnecessary broad-spectrum antibiotic use. (Centers for Disease Control and Prevention [CDC], 2024)
How strong is the patent estate for amoxicillin/clavulanate?
The patent estate is weak for the core product and stronger only at the periphery.
| IP category |
Current commercial strength |
| Core active-ingredient combination |
Low; expired |
| Standard immediate-release tablets |
Low |
| Standard oral suspension |
Low to moderate technical barrier, limited patent strength |
| Pediatric high-dose suspension |
Moderate formulation complexity |
| Extended-release tablets |
Historically stronger, but narrower scope |
| Manufacturing processes |
Potentially relevant, usually difficult to enforce against routine generic entry |
| Method-of-use patents |
Limited commercial impact unless tied to a specific approved label |
| Trade secrets and know-how |
Relevant to yield, stability, and quality control |
A generic applicant can challenge a listed patent through a Paragraph IV certification if it believes the patent is invalid, unenforceable, or not infringed. For this mature product, Paragraph IV activity is more likely to concern a particular strength, formulation, or use than the basic combination.
What patent litigation and settlement agreements affect the product?
The Augmentin franchise generated significant historical patent litigation during the transition to generic competition. Litigation focused on the validity, enforceability, and scope of patents covering the combination and particular formulations.
The commercial effect of that litigation has largely passed. Current generic-entry analysis should focus on:
- Whether a specific product remains listed in the Orange Book.
- Whether the patent covers the generic applicant’s formulation.
- Whether a first-filer has 180-day generic exclusivity.
- Whether a settlement agreement contains launch restrictions or licenses.
- Whether the relevant ANDA has final approval.
Historical settlement agreements may affect timing for individual products, but they do not recreate broad exclusivity for the entire category. A current commercial forecast should not treat legacy Augmentin litigation as an active barrier without confirming the status of the particular patent and ANDA.
What generic entry risks exist for amoxicillin/clavulanate?
Generic-entry risk is already realized for standard products. The primary risk to incumbent suppliers is not a future patent cliff but continued price compression and market-share turnover.
Generic launch scenarios
| Scenario |
Commercial effect |
| Additional tablet suppliers enter |
Lower prices and reduced share for existing suppliers |
| New suspension supplier enters |
Greater pharmacy and wholesaler competition |
| Supply shortage affects a major manufacturer |
Temporary price and volume opportunity for alternate suppliers |
| FDA manufacturing warning or recall |
Rapid channel reallocation |
| Public-sector tender loss |
Large volume decline in affected geography |
| Stewardship-driven prescribing reduction |
Lower unit demand over time |
| Hospital contract win |
Volume increase with limited margin |
Because the product is mature, market access and supply reliability often matter more than patent strategy. A manufacturer with FDA-compliant production, dependable clavulanate supply, and competitive wholesaler terms can gain share without owning meaningful product IP.
What is the financial trajectory for amoxicillin/clavulanate?
The financial trajectory is best characterized as high-volume, low-margin, and resilient rather than high-growth.
Standalone revenue figures are difficult to interpret because companies report amoxicillin/clavulanate within broader generic, established-brand, or anti-infective portfolios. The originator’s historical Augmentin revenue is not a reliable measure of the current generic market. Public company filings generally do not disclose product-level sales for every generic strength and geography.
Revenue drivers
- Persistent outpatient antibiotic demand
- Pediatric and dental prescribing
- Seasonal respiratory and ear infections
- Supply shortages among competing manufacturers
- Hospital and government procurement
- International access programs
- Product availability across multiple dosage forms
Margin pressures
- Large number of suppliers
- Limited differentiation among standard strengths
- Pharmacy benefit manager and wholesaler purchasing power
- Commodity-like active pharmaceutical ingredient economics
- Clavulanate stability and packaging costs
- FDA compliance and remediation costs
- Tender-based price competition
Revenue can rise through volume even when price declines. For manufacturers, profitability depends on capacity utilization, procurement cost, quality yield, freight, channel mix, and whether the product is sold through higher-margin retail, institutional, or public-sector channels.
The category is unlikely to support premium pricing absent a shortage, a differentiated formulation, or a strong local supply position. In the United States, a supplier can achieve meaningful cash generation from scale, but the product is unlikely to provide the return profile associated with a protected specialty drug.
What is the FDA regulatory status of amoxicillin/clavulanate?
Amoxicillin/clavulanate is FDA-approved as a prescription antibacterial drug. The FDA label contains dosage, contraindication, warning, pediatric, renal-impairment, and administration requirements. The product is contraindicated in patients with a history of serious hypersensitivity to beta-lactam antibiotics and in patients with prior cholestatic jaundice or hepatic dysfunction associated with the combination. (FDA, 2023a)
Regulatory risks include:
- Manufacturing deficiencies
- Stability failures, especially for suspension products
- Labeling noncompliance
- Pediatric dosing errors
- Product recalls
- Shortage reporting and supply interruptions
- Antimicrobial-resistance concerns
The product is not subject to biosimilar interchangeability rules. Generic substitution is governed by FDA therapeutic-equivalence determinations and state law.
Where is geographic coverage strongest?
Amoxicillin/clavulanate has broad global coverage, but commercial structure varies by region.
| Region |
Market dynamics |
| United States |
Mature generic market, retail substitution, supply-driven share shifts |
| Europe |
Strong generic and tender competition; national reimbursement controls |
| India |
Large branded-generic market with many local manufacturers |
| Latin America |
Mix of branded generics, private retail, and public procurement |
| Asia-Pacific |
High volume, variable regulatory standards, local manufacturing importance |
| Middle East and Africa |
Public tenders, import dependence, and supply reliability are central |
In lower-income markets, access and procurement price can outweigh brand recognition. In regulated markets, manufacturing compliance and tender performance determine persistence.
Does amoxicillin/clavulanate face biosimilar competition?
No. Amoxicillin/clavulanate is a chemically synthesized small molecule, not a biologic. It faces generic competition through ANDAs and equivalent regulatory pathways outside the United States. The relevant competitive risks are generic launches, therapeutic substitution, local branded generics, and procurement competition.
What licensing deals affect amoxicillin/clavulanate?
The original Augmentin commercial history involved originator development, regional commercialization, and later generic licensing and supply arrangements. Current licensing value is limited for the standard product because the core patents have expired.
Potentially valuable arrangements involve:
- Regional distribution rights
- Government procurement contracts
- Contract manufacturing
- Pediatric formulation technology
- Extended-release delivery systems
- Dual sourcing of amoxicillin and clavulanate
- Local registration and commercialization rights
A licensing transaction for standard immediate-release tablets would generally be volume- and geography-driven rather than IP-driven.
Key Takeaways
- Amoxicillin/clavulanate is a mature, high-volume generic antibiotic market.
- The core Augmentin patent position expired years ago, with U.S. combination protection ending around 2002.
- Standard tablets and suspensions have low patent strength and high generic-entry exposure.
- Extended-release and pediatric formulations may have more technical complexity, but they do not support broad franchise exclusivity.
- The product has no biosimilar risk because it is a small molecule.
- Financial performance depends on volume, supply reliability, tenders, reimbursement, and manufacturing efficiency.
- Broad-spectrum stewardship policies limit unnecessary use but do not eliminate durable clinical demand.
- Future value is more likely to come from operational scale, geographic distribution, and reliable supply than from patents.
Frequently Asked Questions
Is Augmentin still patent protected?
The original broad Augmentin combination protection is expired. Any current patent issue must be evaluated by specific strength, formulation, method of use, and Orange Book listing.
Can generic amoxicillin/clavulanate be substituted for Augmentin?
FDA-rated therapeutically equivalent products may generally be substituted, subject to the dosage form, strength, state pharmacy law, and prescriber instructions.
Why is amoxicillin/clavulanate more expensive than amoxicillin?
Clavulanate adds an active ingredient, formulation complexity, stability requirements, and manufacturing cost. The combination also has a broader labeled antibacterial spectrum.
Is amoxicillin/clavulanate a good generic drug market?
It is commercially durable but price competitive. Scale, reliable production, and access to retail or institutional channels matter more than product patents.
What could increase amoxicillin/clavulanate revenue?
Revenue can increase through market share gains, supply shortages affecting competitors, new geographic registrations, pediatric or extended-release products, procurement contracts, and improved manufacturing utilization.
References
-
Centers for Disease Control and Prevention. (2024). Outpatient clinical care for adults and pediatric patients: Antibiotic prescribing and use. https://www.cdc.gov/antibiotic-use/hcp/clinical-care/
-
U.S. Food and Drug Administration. (2023a). Augmentin prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Patent No. 4,525,352. (1985). Antibacterial compositions containing clavulanic acid. United States Patent and Trademark Office.
